Raised CD40L expression attenuates drug resistance in Adriamycin‑resistant THP‑1 cells

Feng,Zhongxin; Chen,Qi

doi:10.3892/etm.2020.8452

Raised CD40L expression attenuates drug resistance in Adriamycin‑resistant THP‑1 cells

Authors:
- Zhongxin Feng
- Qi Chen
View Affiliations

Affiliations: Department of Hematology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563003, P.R. China
Published online on: January 15, 2020 https://doi.org/10.3892/etm.2020.8452
Pages: 2188-2194
Copyright: © Feng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Acute myeloid leukemia is a common hematological malignancy that often exhibits strong drug resistance when treated using conventional chemotherapy. Although numerous studies have been carried out to develop methods of overcoming drug resistance, the results have generally been unsatisfactory. CD40 ligand (CD40L) has been shown to improve the sensitivity of cancer cells to drug treatment. In the present study, Adriamycin (ADM)‑resistant human monocytic THP‑1 cells (THP‑1/A cells) were developed by incubating THP‑1 cells with increasing concentrations of ADM. Cells were transfected with CD40L vectors to explore the potential involvement of CD40L in regulating multidrug resistance (MDR) in cancer. Cell proliferation and viability were measured using the Cell Counting Kit‑8 assay; cell apoptosis was evaluated by flow cytometry, trypan blue staining and caspase‑3 activity; and the expression of MDR‑associated protein 1 (MRP1) and permeability glycoprotein (P‑gp) was analyzed using western blotting. The results revealed that the protein expression levels of MRP1 and P‑gp were downregulated by raised CD40L expression and that the combination of raised CD40L expression with daunorubicin (DNR), a drug from which ADM is derived, significantly increased the extent of cell apoptosis, indicating that drug resistance was effectively attenuated by CD40L. Collectively, these results suggested that CD40L may contribute towards reducing DNR resistance in THP‑1/A cells.

View Figures

View References

1	Ferrara F and Schiffer CA: Acute myeloid leukaemia in adults. Lancet. 381:484–495. 2013. View Article : Google Scholar : PubMed/NCBI
2	Walter RB, Othus M, Burnett AK, Löwenberg B, Kantarjian HM, Ossenkoppele GJ, Hills RK, van Montfort KG, Ravandi F, Evans A, et al: Significance of FAB subclassification of ‘acute myeloid leukemia, NOS’ in the 2008 WHO classification: Analysis of 5848 newly diagnosed patients. Blood. 121:2424–2431. 2013. View Article : Google Scholar : PubMed/NCBI
3	Pession A, Martino V, Tonelli R, Beltramini C, Locatelli F, Biserni G, Franzoni M, Freccero F, Montemurro L, Pattacini L and Paolucci G: MLL-AF9 oncogene expression affects cell growth but not terminal differentiation and is downregulated during monocyte-macrophage maturation in AML-M5 THP-1 cells. Oncogene. 22:8671–9676. 2003. View Article : Google Scholar : PubMed/NCBI
4	Basara N, Schulze A, Wedding U, Mohren M, Gerhardt A, Junghanss C, Peter N, Dölken G, Becker C, Heyn S, et al: Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission. Leukemia. 23:635–640. 2009. View Article : Google Scholar : PubMed/NCBI
5	Magenau J and Couriel DR: Hematopoietic stem cell transplantation for acute myeloid leukemia: To whom, when, and how. Curr Oncol Rep. 15:436–444. 2013. View Article : Google Scholar : PubMed/NCBI
6	Hassan GS, Stagg J and Mourad W: Role of CD154 in cancer pathogenesis and immunotherapy. Cancer Treat Rev. 41:431–440. 2015. View Article : Google Scholar : PubMed/NCBI
7	Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y and Noelle RJ: Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 229:152–172. 2009. View Article : Google Scholar : PubMed/NCBI
8	Korniluk A, Kemona H and Dymicka-Piekarska V: Multifunctional CD40L: Pro- and anti-neoplastic activity. Tumour Biol. 35:9447–9457. 2014. View Article : Google Scholar : PubMed/NCBI
9	Li R, Chen WC, Wang WP, Tian WY and Zhang XG: CD40 signaling activated by agonistic anti-CD40 monoclonal antibody 5C11 has different effects on biological behavior of gastric carcinoma cells. Immunol Lett. 131:120–125. 2010. View Article : Google Scholar : PubMed/NCBI
10	Zhou Y, Ling XL, Li SW, Li XQ and Yan B: Establishment of a human hepantoma multidrug resistant cell line in vitro. World J Gastroenterol. 16:2291–2297. 2010. View Article : Google Scholar : PubMed/NCBI
11	Zheng TT, Pan ZH, Zheng XS, et al: Establishment and drug resistance of adriamycin-resistant breast cancer MCF-7/Adm cell line. J Zhejiang Sci Tech Univ. 31:216–219. 2014.(In Chinese).
12	Li DY: Effects of overexpression of CD40L gene on proliferation, apoptosis and drug resistance of Kasumi-1/ADM cell line. Zunyi Med Coll. 2016.(In Chinese).
13	Aldinucci D, Poletto D, Nanni P, Degan M, Rupolo M, Pinto A and Gattei V: CD40L induces proliferation, self-renewal, rescue from apoptosis, and production of cytokines by CD40-expressing AML blasts. Exp Hematol. 30:1283–1292. 2002. View Article : Google Scholar : PubMed/NCBI
14	Marie JP, Huet S, Faussat AM, Perrot JY, Chevillard S, Barbu V, Bayle C, Boutonnat J, Calvo F, Campos-Guyotat L, et al: Multicentric evaluation of the MDR phenotype in leukemia French network of the drug resistance intergroup, and drug resistance network of assistance publique-hôpitaux de Paris. Leukemia. 11:1086–1094. 1997. View Article : Google Scholar : PubMed/NCBI
15	Sun Y, Wang C, Meng Q, Liu Z, Huo X, Sun P, Sun H, Ma X, Peng J and Liu K: Targeting P-glycoprotein and SORCIN: Dihydromyricetin strengthens anti-proliferative efficiency of Adriamycin via MAPK/ERK and Ca 2+ -mediated apoptosis pathways in MCF-7/ADR and K562/ADR. J Cell Physiol. 233:3066–3079. 2018. View Article : Google Scholar : PubMed/NCBI
16	Styczyński J, Wysocki M, Debski R, Balwierz W, Rokicka-Milewska R, Matysiak M, Balcerska A, Kowalczyk J, Wachowiak J, Sońta-Jakimczyk D and Chybicka A: Cross-resistance to five glucocorticoids in childhood acute lymphoblastic and non-lymphoblastic leukemia samples tested by the MTT assay: Preliminary report. Acta Biochim Pol. 49:93–98. 2002. View Article : Google Scholar : PubMed/NCBI
17	Rees DC, Johnson E and Lewinson O: ABC transporters: The power to change. Nat Rev Mol Cell Biol. 10:218–227. 2009. View Article : Google Scholar : PubMed/NCBI
18	Benabbou N, Mirshahi P, Bordu C, Faussat AM, Tang R, Therwath A, Soria J, Marie JP and Mirshahi M: A subset of bone marrow stromal cells regulate ATP-binding cassette gene expression via insulin-like growth factor-I in a leukemia cell line. Int J Oncol. 45:1372–1380. 2014. View Article : Google Scholar : PubMed/NCBI
19	Fletcher JI, Williams RT, Henderson MJ, Norris MD and Haber M: ABC transporters as mediators of drug resistance and contributors to cancer cell biology. Drug Resist Updat. 26:1–9. 2016. View Article : Google Scholar : PubMed/NCBI
20	Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM and Slapak CA: An increase in the expression of ribonucleotide teductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res. 64:3761–3766. 2004. View Article : Google Scholar : PubMed/NCBI
21	Qin L, Qiu H, Zhang M, Zhang F, Yang H, Yang L, Jia L, Qin K, Jia L, Dou X, et al: Soluble CD40 ligands sensitize the epithelial ovarian cancer cells to cisplatin treatment. Biomed Pharmacother. 79:166–175. 2016. View Article : Google Scholar : PubMed/NCBI
22	Liljenfeldt L, Gkirtzimanaki K, Vyrla D, Svensson E, Loskog AS and Eliopoulos AG: Enhanced therapeutic anti-tumor immunity induced by co-administration of 5-fluorouracil and adenovirus expressing CD40 ligand. Cancer Immunol Immunother. 63:273–282. 2014. View Article : Google Scholar : PubMed/NCBI
23	Chen C, Xu W and Wang CM: Combination of celecoxib and doxorubicin increases growth inhibition and apoptosis in acute myeloid leukemia cells. Leuk Lymphoma. 54:2517–2522. 2013. View Article : Google Scholar : PubMed/NCBI
24	Pophali P and Litzow M: What is the best daunorubicin dose and schedule for acute myeloid leukemia induction? Curr Treat Options Oncol. 18:32017. View Article : Google Scholar : PubMed/NCBI
25	Chanput W, Mes JJ and Wichers HJ: THP-1 cell line: An in vitro cell model for immune modulation approach. Int Immunopharmacol. 23:37–45. 2014. View Article : Google Scholar : PubMed/NCBI
26	Zhang YK, Wang YJ, Gupta P and Chen ZS: Multidrug resistance proteins (MRPs) and cancer therapy. AAPS J. 17:802–812. 2015. View Article : Google Scholar : PubMed/NCBI
27	Binkhathlan Z and Lavasanifar A: P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: Current status and future perspectives. Curr Cancer Drug Targets. 13:326–346. 2013. View Article : Google Scholar : PubMed/NCBI
28	Tsuruo T, Iida H, Tsukagoshi S and Sakurai Y: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41:1967–1972. 1981.PubMed/NCBI
29	Mickisch GH, Noordzij MA, vd Gaast A, Gebreamlack P, Köhrmann KU, Mogler-Drautz E, Kupper H and Schröder FH: Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma. J Cancer Res Clin Oncol. 121 (Suppl 3):R11–R16. 1995. View Article : Google Scholar : PubMed/NCBI
30	Thomas H and Coley HM: Overcoming multidrug resistance in cancer: An update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control. 10:159–165. 2003. View Article : Google Scholar : PubMed/NCBI
31	Martelli C, Coronnello M, Dei S, Manetti D, Orlandi F, Scapecchi S, Novella Romanelli M, Salerno M, Mini E and Teodori E: Structure-activity relationships studies in a series of N,N-bis(alkanol)amine aryl esters as P-glycoprotein (Pgp) dependent multidrug resistance (MDR) inhibitors. J Med Chem. 53:1755–1762. 2010. View Article : Google Scholar : PubMed/NCBI
32	Dei S, Romanelli MN, Manetti D, Chiaramonte N, Coronnello M, Salerno M and Teodori E: Design and synthesis of aminoester heterodimers containing flavone or chromone moieties as modulators of P-glycoprotein-based multidrug resistance (MDR). Bioorg Med Chem. 26:50–64. 2018. View Article : Google Scholar : PubMed/NCBI
33	Styczynski J, Wysocki M, Debski R, Kurylak A, Balwierz W, Rokicka-Milewska R, Matysiak M, Balcerska A, Kowalczyk J, Wachowiak J, et al: The influence of intracellular Idarubicin and daunorubicin levels on drug cytotoxicity in childhood acute leukemia. Acta Biochim Pol. 49:99–107. 2002. View Article : Google Scholar : PubMed/NCBI
34	Styczynski J, Toporski J, Wysocki M, Debski R, Chybicka A, Boruczkowski D, Wachowiak J, Wojcik B, Kowalczyk J, Gil L, et al: Fludarabine, treosulfan and etoposide sensitivity and the outcome of hematopoietic stem cell transplantation in childhood acute myeloid leukemia. Anticancer Res. 27:1547–1551. 2007.PubMed/NCBI